These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35513605)

  • 1. [
    Vigne J; Chrétien B; Bignon AL; Bouhier-Leporrier K; Dolladille C
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3332-3333. PubMed ID: 35513605
    [No Abstract]   [Full Text] [Related]  

  • 2. Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy.
    de Vries-Huizing DMV; Cheung ZJ; Hendrikx JJMA; Donswijk ML; Versleijen MWJ
    Clin Nucl Med; 2024 May; 49(5):454-456. PubMed ID: 38465961
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Abbott A; Jacene H
    J Nucl Med Technol; 2022 Sep; 50(3):203-204. PubMed ID: 36215643
    [No Abstract]   [Full Text] [Related]  

  • 4. Striking Size Reduction of Rapidly Growing Pancreatic Neuroendocrine Carcinoma Metastatic Nodal Conglomerate After Only 2 Cycles of 177 Lu-DOTATATE.
    Somoza EA; Duan H; Shaheen S; Fischer GA; Aparici CM
    Clin Nucl Med; 2022 Nov; 47(11):961-962. PubMed ID: 35695695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm.
    Bober B; Saracyn M; Lubas A; Kolodziej M; Brodowska-Kania D; Kapusta W; Kaminski G
    Nucl Med Rev Cent East Eur; 2022; 25(1):54-61. PubMed ID: 35137938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (
    Kovan B; Özkan ZG; Demir B; Tunçman D; Işik EG; Şimşek DH; Büyükkaya F; Türkmen C; Şanli Y
    Cancer Biother Radiopharm; 2022 Feb; 37(1):17-22. PubMed ID: 34134512
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE.
    Pirisino R; Filippi L; D'Agostini A; Bagni O
    Clin Nucl Med; 2022 Nov; 47(11):e692-e695. PubMed ID: 35695716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
    Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
    Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of
    Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G
    J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Hervás I; Bello P; Falgas M; Del Olmo MI; Torres I; Olivas C; Vera V; Oliván P; Yepes AM
    Rev Esp Med Nucl Imagen Mol; 2017; 36(2):91-98. PubMed ID: 27889527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
    Delpassand ES; Samarghandi A; Zamanian S; Wolin EM; Hamiditabar M; Espenan GD; Erion JL; O'Dorisio TM; Kvols LK; Simon J; Wolfangel R; Camp A; Krenning EP; Mojtahedi A
    Pancreas; 2014 May; 43(4):518-25. PubMed ID: 24632546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
    Ianniello A; Sansovini M; Severi S; Nicolini S; Grana CM; Massri K; Bongiovanni A; Antonuzzo L; Di Iorio V; Sarnelli A; Caroli P; Monti M; Scarpi E; Paganelli G
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1040-6. PubMed ID: 26611427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Instability of
    Lubberink M; Wilking H; Öst A; Ilan E; Sandström M; Andersson C; Fröss-Baron K; Velikyan I; Sundin A
    J Nucl Med; 2020 Sep; 61(9):1337-1340. PubMed ID: 32005767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
    Gupta SK; Singla S; Bal C
    Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino acid extravasation: a rare red flag to keep in mind during peptide receptor radioligand therapy (PRRT) with [177Lu]Lu-DOTATATE.
    Divband G; Alavi SH; Adinehpour Z; Kalantari F; Zarehparvar Moghadam S
    Nucl Med Rev Cent East Eur; 2022; 25(2):136-137. PubMed ID: 35848524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
    Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
    Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Kulkarni HR; Schuchardt C; Baum RP
    Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.